(VIANEWS) – MetLife (MET), Oaktree Specialty Lending Corporation (OCSL), Cohn & Steers (CNS) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio at the moment. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. MetLife (MET)
469.77% Payout Ratio
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, MetLife has a trailing twelve months EPS of $0.43.
PE Ratio
MetLife has a trailing twelve months price to earnings ratio of 145.2. Meaning, the purchaser of the share is investing $145.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.47%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Aug 6, 2023, the estimated forward annual dividend rate is 2.08 and the estimated forward annual dividend yield is 3.36%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 72.7% and 39.4%, respectively.
Yearly Top and Bottom Value
MetLife’s stock is valued at $62.44 at 02:23 EST, way under its 52-week high of $77.36 and way above its 52-week low of $48.95.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MetLife’s EBITDA is 0.69.
Previous days news about MetLife (MET)
- Metlife (met), empathy to offer enhanced bereavement services. According to Zacks on Wednesday, 23 August, "Additionally, the recent move of MetLife can also be termed as a time opportune one as well, considering the substantial time that bereaved families have to dedicate for addressing administrative burdens. ", "Shares of MetLife have gained 22% in the past three months compared with the industry’s 6.4% growth. "
2. Oaktree Specialty Lending Corporation (OCSL)
174.8% Payout Ratio
Oaktree Specialty Lending Corporation is a business development company specializing in investments in middle market, bridge financing, first and second lien debt financing, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, and management buyouts in small and mid-sized companies. The fund seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering, and media and advertising sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies with enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies.
Earnings Per Share
As for profitability, Oaktree Specialty Lending Corporation has a trailing twelve months EPS of $0.11.
PE Ratio
Oaktree Specialty Lending Corporation has a trailing twelve months price to earnings ratio of 181.27. Meaning, the purchaser of the share is investing $181.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.1%.
3. Cohn & Steers (CNS)
76.71% Payout Ratio
Cohen & Steers, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries. The firm launches and manages equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. Through its subsidiaries, it also launches and manages hedge funds. The firm invests in public equity, fixed income, and commodity markets across the globe through its subsidiaries. Through its subsidiaries, it invests in companies operating in the real estate sector, including real estate investment trusts, infrastructure sector, and natural energy resources sector for its equity and fixed income investments. The firm also invests in preferred securities for its fixed income investments through its subsidiaries. Cohen & Steers, Inc. was founded in 1986 and is based in New York, with additional offices in London, United Kingdom; Central, Hong Kong; Tokyo, Japan; and Seattle, Washington.
Earnings Per Share
As for profitability, Cohn & Steers has a trailing twelve months EPS of $2.92.
PE Ratio
Cohn & Steers has a trailing twelve months price to earnings ratio of 21.8. Meaning, the purchaser of the share is investing $21.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.61%.
4. Gilead Sciences (GILD)
68.05% Payout Ratio
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Earnings Per Share
As for profitability, Gilead Sciences has a trailing twelve months EPS of $4.35.
PE Ratio
Gilead Sciences has a trailing twelve months price to earnings ratio of 17.73. Meaning, the purchaser of the share is investing $17.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.35%.
Moving Average
Gilead Sciences’s worth is below its 50-day moving average of $77.63 and below its 200-day moving average of $81.44.
Previous days news about Gilead Sciences (GILD)
- According to MarketWatch on Wednesday, 23 August, "Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. , Arcus Biosciences Inc. and iTeos Therapeutics Inc. , got a boost premarket on Wednesday after Roche AG said there had been an "inadvertent disclosure" of interim data from a study of its anti-TIGIT therapy tiragolumab in non-small cell lung cancer. "
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1% and 1%, respectively.
